Overview

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

Status:
Not yet recruiting
Trial end date:
2022-09-27
Target enrollment:
Participant gender:
Summary
Relative bioavailability study to evaluate the pharmacokinetics of two new encorafenib formulations
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Collaborators:
Ono Pharmaceutical Co. Ltd
Pierre Fabre Laboratories
Treatments:
Rabeprazole